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Abstract
Background: Influenza and pneumococcal vaccination are recommended for a number of clinical
risk groups including patients treated with major immunosuppressant disease modifying anti-
rheumatic drugs. Such immunisation is not only safe but immunogenic in patients with rheumatic
diseases. We sought to establish dual vaccination rates and significant influencing factors amongst
our hospital rheumatology outpatients.
Method: We audited a sample of 101 patients attending hospital rheumatology outpatient clinics
on any form of disease modifying treatment by clinical questionnaire and medical record perusal.
Further data were collected from the local immunisation coordinating agency and analysed by
logistic regression modelling.
Results: Although there was a high rate of awareness with regard to immunisation, fewer patients
on major immunosuppressants were vaccinated than patients with additional clinical risk factors
against influenza (53% vs 93%, p < 0.001) or streptococcus pneumoniae (28% vs 64%, p = 0.001).
The presence of additional risk factors was confirmed as significant in determining vaccination
status by logistic regression for both influenza (OR 10.89, p < 0.001) and streptococcus
pneumoniae (OR 4.55, p = 0.002). The diagnosis of rheumatoid arthritis was also found to be a
significant factor for pneumococcal vaccination (OR 5.1, p = 0.002). There was a negative trend
suggesting that patients on major immunosuppressants are less likely to be immunised against
pneumococcal antigen (OR 0.35, p = 0.067).
Conclusion: Influenza and pneumococcal immunisation is suboptimal amongst patients on current
immunosuppressant treatments attending rheumatology outpatient clinics. Raising awareness
amongst patients may not be sufficient to improve vaccination rates and alternative strategies such
as obligatory pneumococcal vaccination prior to treatment initiation and primary care provider
education need to be explored.
Background
Influenza infection is responsible for considerable mor-
bidity and mortality in epidemic years [1], whilst strepto-
coccus pneumoniae infection accounts for 48% of
bacteriologically confirmed community acquired pneu-
monias [2]. A number of groups have been identified as
being at high risk for whom vaccination is currently rec-
ommended in the United Kingdom (UK), including indi-
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viduals over 65 years of age or with heart disease, chronic
lung disease, diabetes, chronic renal failure, chronic liver
failure or hyposplenism [3]. Patients with inflammatory
rheumatic diseases have an increased incidence of infec-
tions [4] including those of the respiratory tract [5]. Treat-
ment with corticosteroids and some other Disease
Modifying Anti-Rheumatic Drugs (DMARDs) has been
implicated as contributing to the increased susceptibility
to infection [5,6]. More recently, this has also been high-
lighted for biologic therapies targeting tumour necrosis
alpha inflammatory pathways [7]. Both influenza and
pneumococcal vaccination are safe and immunogenic in
patients with rheumatic diseases who are taking DMARDs
[8-11]. National UK guidelines specifically recommend
immunisation for patients on systemic steroids at a dose
of 20 mg or more [3]. It is our unit's current policy to pro-
vide patients started on other DMARDs with written infor-
mation (Arthritis Research Campaign, UK) advising
influenza and pneumococcal immunisation for major
immunosuppressants in line with national guidance [12]
although we neither provide a vaccination service nor
withhold major immunosuppressant DMARD treatment
until the patient is vaccinated. Influenza vaccine uptake
has previously been noted to be as low as 56% amongst
rheumatoid arthritis patients on major immunosuppres-
sant therapies [13] whilst uptake amongst the over 65 year
age group in the year 2005–6 was 75% for influenza and
64% for pneumococcal vaccine in the UK [14] prompting
us to audit immunisation rates for both influenza and
pneumococcal vaccine amongst all patients attending out-
patient rheumatology clinics at our district general hospi-
tal and explore associated influencing factors.
Methods
Patients were eligible for inclusion if they were on
DMARD treatments including systemic corticosteroids
(over 20 mg per day for at least 1 month in the last 12
months) and biologic therapy whilst attending a doctor or
nurse-led adult rheumatology outpatient clinic at our dis-
trict general hospital. No exclusion criteria were specified.
A single page questionnaire gathering information on
general practitioner, age, gender, rheumatological diagno-
sis, significant comorbidities, current treatment, vaccina-
tion awareness, vaccination status (influenza vaccine in
the previous 12 months and pneumococcal vaccine in the
previous 5 years) and underlying motive for vaccine
refusal if applicable was created to standardise data collec-
tion amongst auditors. A large practice was defined as a
general practice at which more than 6 audit patients were
registered. Whilst the questionnaire was not formally val-
idated prior to the study, its design was discussed with our
clinical audit department and then reviewed in the initial
stages of the project. No questionnaire modifications were
deemed necessary and the audit was continued as initially
planned. Our patient recruitment strategy was designed to
maximise the number of audited patients over a short
period of time. To this end, questionnaires were simulta-
neously distributed to two nurse practitioners, two spe-
cialist registrars and one consultant in our rheumatology
department in September 2006. Individual auditors then
consecutively screened and selected for audit suitable
patients attending their respective outpatient clinics until
a predefined target of 100 audited patients was achieved
in October 2006. Data were collected from patient inter-
view and available hospital records by individual auditors
at the time of clinical review. There were no recorded
instances of refusal to participate in our audit by a patient.
Additional corroborative information was sought from
the immunisation coordinating Lancashire and South
Cumbria Agency, Preston, UK. This was released to our
clinical audit department after formal approval by our
appointed Caldicott guardian in charge of patient data
protection, merged with interview data and then released
in anonymised format to the investigators. Formal
approval to carry out this audit was sought and granted by
our clinical audit department. The Statistical analysis was
performed using software supplied by Minitab Inc, USA
and Creostat HB, Sweden.
Results
The main characteristics of our sample of 101 patients are
summarised in table 1. The age range was 32 to 87 years
with a mean age of 60.6 years. There was a predominance
of female patients and patients attending large general
practices. A rheumatological diagnosis was available for
99 patients and 4 of these had more than one diagnosis.
The main diagnostic group consisted of rheumatoid
arthritis, with psoriatic arthritis and polymyalgia rheu-
matica (PMR) or giant cell arteritis (GCA) representing
two-thirds of the remaining diagnoses. In total 56 patients
had additional risk factors (other than major immuno-
suppressant DMARDs) for which influenza or pneumo-
coccal immunisation are usually indicated. There were 33
patients over 65 years of age thus making age the most fre-
quent of these risk factors and accounting for 59% of
patients in this group. Methotrexate was the most com-
monly encountered DMARD drug in 48 patients and 27
patients were on a combination of two or more agents. We
identified 76 patients on major immunosuppressant
DMARDs (methotrexate, leflunomide, cyclosporine, aza-
thioprine, biologics and corticosteroids) for whom
immunisation is considered to be indicated and 25
patients on minor immunosuppressant DMARDs (sul-
phasalazine, penicillamine, hydroxychloroquine and
gold) for whom immunisation is not considered indi-
cated.
We compared the vaccination profile of patients with and
without additional risk factors according to their use of
major immunosuppressant DMARDs as shown in Table 2.BMC Musculoskeletal Disorders 2007, 8:58 http://www.biomedcentral.com/1471-2474/8/58
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Amongst our audit sample 45 patients had no additional
risk factors amongst which 32 were on major immuno-
suppressant DMARDs. Awareness of individual need for
immunisation was generally high, even in patients with
no additional risk factors and on minor immunosuppres-
sant DMARDs. Nevertheless, fewer patients on major
immunosuppressant DMARDs were offered immunisa-
tions than patients with additional risk factors (p < 0.001)
as evidenced by the influenza and pneumococcal immu-
nisation rates with 93% vs 53% (p < 0.001) and 64% vs
28% (p = 0.001) of patients being vaccinated against
influenza and streptococcus pneumoniae respectively.
Interestingly, the proportion of influenza vaccinated
patients on major immunosuppressant DMARDs without
additional risk factors is not significantly different from
that of patients on minor immunosuppressant DMARDs
(53% vs 54%, p = 0.965), as was also the case for pneu-
mococcal vaccine (28% vs 38%, p = 0.497). Amongst
patients offered influenza or pneumococcal immunisa-
tion by their general practitioners, overall uptake of influ-
enza or pneumococcal vaccine was 90%, with only 4
patients refusing their influenza or pneumococcal vacci-
nation offers. Stated reasons for refusal included vaccine
allergy, patient belief that vaccination was unnecessary or
that vaccination was contraindicated.
We investigated the factors influencing immunisation
amongst our sample of patients by logistic regression
modelling using presence of additional risk factor, size of
general practice, diagnosis of rheumatoid arthritis, major
immunosuppressant drug therapy and gender as predictor
variables. Results are displayed in tables 3 and 4.
In the case of influenza vaccination the presence of an
additional risk factor (OR 10.89, 95% CI 3.24–36.65) was
the only significant factor influencing the odds ratio for
immunisation, whilst a trend was apparent for large prac-
tices (OR 2.78, 95% CI 0.92–8.36). There was no detecta-
ble effect of major immunosuppressant use.
Significant factors influencing pneumococcal vaccination
included a diagnosis of rheumatoid arthritis (OR 5.10,
95% CI 1.78–14.59) and the presence of additional risk
factors (OR 4.53, 95% CI 1.76–11.62). There was a nota-
ble negative trend for the odds ratio with major immuno-
suppressant use (OR 0.35, 95% CI 0.11–1.07).
Discussion
Given the increased susceptibility to infection amongst
patients with inflammatory rheumatic diseases and the
potential to counteract this risk with influenza and pneu-
mococcal vaccination, it is important to ascertain the
effect that current education and immunisation practice
are having on rheumatology patients.
Our audit has shown a high rate of immunisation aware-
ness amongst our patients as could be expected from our
unit's policy of routinely counselling patients starting dis-
ease modifying treatments and providing written drug
information leaflets. A small number of patients on minor
immunosuppressant DMARD therapy and without addi-
Table 2: Vaccination profile of sample population (%)
Total Awareness GP offer Influenza immunisation Pneumococcal immunisation
No risk factor + Minor immunosuppressant 13 10 (77) 8 (62) 7(54) 5(38)
No risk factor + Major Immunosuppressant 32 26 (81) 17 (53) 17(53) 9(28)
Risk factor + Any Immunosuppressant 56 55 (98) 53 (95) 52(93) 36(64)
Chi-square test of association - - p < 0.001 p < 0.001 p = 0.003
Table 1: Main characteristics of sample population
Demographics
Total number of patients 101
Age range in years (mean) 32–87 (60.6)
Female 70
Registered to Large Practice 54
Diagnosis
Rheumatoid Arthritis 71
Psoriatic Arthritis 11
PMR or GCA 9
SLE 6
Other 6
Risk factors
>65 years 33
Chronic lung disease 16
Ischaemic heart disease 12
Diabetes 11
Any risk factor 56
DMARD therapy
Immunosuppressant1 76
Non-immunosuppressant2 25
1Methotrexate, Leflunomide, Cyclosporine, Azathioprine, Biologic, 
Steroid
2 Sulphasalazine, Penicillamine, Hydroxychloroquine, GoldBMC Musculoskeletal Disorders 2007, 8:58 http://www.biomedcentral.com/1471-2474/8/58
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tional risk factors requiring immunisation believed they
needed vaccinating and this was reflected in their rate of
vaccination offer and uptake. Information on risk factors
was collected by direct patient questioning with access to
clinical records during patient consultation, and it would
seem unlikely that any major risk factors would have been
missed in the audit process thus raising the possibility that
the perceived immunosuppressant effects of rheumatic ill-
ness or the perceived risk of minor immunosuppressant
drug therapy may be affecting patients' and their family
physicians' immunisation strategies. The first possibility is
supported by finding rheumatoid arthritis to be a signifi-
cant factor influencing pneumococcal vaccination rates
through our logistic regression model. A number of our
patients will inevitably eventually turn to major immuno-
suppressant DMARDs as rescue therapies and we are
therefore not concerned by what appears to be over-vacci-
nation on the part of our general practitioner colleagues.
Patients who are on major immunosuppressants are nev-
ertheless less commonly offered vaccination or vaccinated
as compared to patients with other risk factors despite the
high levels of patient awareness and uptake suggesting
that a proportion of our high risk patients are not actively
pursuing known immunisation advice nor being correctly
identified by their family physicians. Notwithstanding
our small audit sample size, there is even a trend suggest-
ing that major immunosuppressant use may be an inde-
pendent negating factor in the setting of pneumococcal
vaccination. Interestingly, patients belonging to larger
general practices with higher numbers of rheumatology
patients are likely to achieve better coverage for influenza
immunisation and this may suggest that organisational
factors in individual practices may play an important role
here.
As influenza vaccination is seasonal, it would be imprac-
tical and difficult given our limited resources to offer
annual immunisation directly in our rheumatology out-
patient clinics when there are funded agencies dedicated
to this purpose operating within our area. There is also a
concern that patients could unnecessarily be vaccinated
more than once by different providers and for these rea-
sons we maintain that responsibility for immunisation
should continue to rest with primary care providers. As
immunosuppressant therapy is mostly initiated in rheu-
matology outpatient clinics, one possible approach to
improve current practice and perhaps immunisation effi-
cacy would be to routinely request patient vaccination
prior to rather than after the initiation of major immuno-
suppressant therapy as we do at present. Whilst feasible
for pneumococcal vaccine, this approach may be limited
by the availability of influenza vaccine outwith the immu-
nisation calendar. We would therefore also recommend
contacting primary health care providers before the start
of each annual immunisation season to raise general
awareness about the need to vaccinate any patient on
major immunosuppressant therapy in order improve tar-
geting of existing rheumatology patients in the commu-
nity.
Conclusion
Rheumatology outpatients are not being appropriately
targeted by the influenza and pneumococcal vaccination
efforts on the part of primary care physicians. Raising
patient awareness is not sufficient to ensure optimal
immunisation thus calling for alternative strategies on the
part of rheumatology services to improve vaccination cov-
erage
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Table 4: Factors influencing pneumococcal vaccination
Odds Ratio 95% CI P value
Rheumatoid arthritis 5.10* 1.78–14.59 0.002
Risk factor 4.53* 1.76–11.62 0.002
Large Practice 0.80 0.31–2.06 0.646
Female 0.75 0.27–2.10 0.583
Major Immunosuppressant# 0.35 0.11–1.07 0.067
#Methotrexate, Leflunomide, Cyclosporine, Azathioprine, Biologic, 
Steroid
* Significant result (p < 0.05)
Table 3: Factors influencing influenza vaccination
Odds Ratio 95% CI P value
Risk factor 10.89* 3.24–36.65 <0.001
Large Practice 2.78 0.92–8.36 0.069
Rheumatoid Arthritis 1.50 0.48–4.69 0.489
Female 0.90 0.25–3.26 0.871
Major Immunosuppressant# 0.63 0.18–2.20 0.472
#Methotrexate, Leflunomide, Cyclosporine, Azathioprine, Biologic, 
Steroid
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